Millions of US adults suffering from heartburn associated with non-erosive-gastroesophageal-reflux-disease (GERD) could benefit from an impending treatment by Phathom Pharmaceuticals.
The NDA submission was supported by positive data from the phase 3 PHALCON-NERD-301 study and has been assigned a standard 10-month review with a PDUFA target action date of July 19, 2024.
Phathom Pharma (PHAT) Announces FDA Acceptance for Filing of VOQUEZNA Tablets NDA for Treatment of Heartburn Associated with Non-Erosive GERD streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Evercore ISI upgraded shares of Phathom Pharmaceuticals (NASDAQ:PHAT – Get Rating) from an in-line rating to an outperform rating in a research note released on Thursday morning, The Fly reports. Several other research analysts have also recently weighed in on the company. Craig Hallum started coverage on Phathom Pharmaceuticals in a research report on Monday, […]
Shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT – Get Rating) have been given an average rating of “Moderate Buy” by the seven analysts that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12-month […]